Inada M, Yamashita J, Nakano S, Ogawa M
Department of Surgery II, Kumamoto University School of Medicine, Kumamoto, Japan.
Anticancer Res. 1998 Mar-Apr;18(2A):885-90.
We previously reported that EBC-1, a non-small cell lung cancer (NSCLC) cell line, produces immunoreactive neutrophil elastase (NE). In the present study, we examined the effects of ONO-5046.Na, a specific NE inhibitor, on the in vivo growth and spontaneous pulmonary metastasis of EBC-1 transplanted into severe combined immunodeficiency (scid) mice. In control mice, EBC-1 tumors inoculated subcutaneously grew steadily throughout 8-week observation period. The daily intraperitoneal injection of ONO-5046.Na (50 mg/kg/day) from day 1 completely suppressed the tumor growth. When ONO-5046.Na treatment was initiated 14 days after EBC-1 inoculation, it also caused a significant delayed growth of this cell line. Furthermore, ONO-5046.Na treatment completely inhibits the appearance of metastatic foci in lung at 8 weeks not only when it was administered from day 1 but also when treatment was initiated 14 days after tumor inoculation, when solid tumors started to grow. The weight of the mice treated with ONO-5046.Na was similar to that of the control mice at 8 weeks, and they appeared as healthy as the control mice during the treatment. These results indicated that a NE inhibitor, ONO-5046.Na, inhibited both primary and metastatic growth of NSCLC with no marked side effects.
我们之前报道过,非小细胞肺癌(NSCLC)细胞系EBC-1可产生免疫反应性中性粒细胞弹性蛋白酶(NE)。在本研究中,我们检测了特异性NE抑制剂ONO-5046.Na对移植到严重联合免疫缺陷(scid)小鼠体内的EBC-1的体内生长及自发性肺转移的影响。在对照小鼠中,皮下接种的EBC-1肿瘤在整个8周观察期内稳定生长。从第1天开始每日腹腔注射ONO-5046.Na(50 mg/kg/天)可完全抑制肿瘤生长。当在接种EBC-1 14天后开始ONO-5046.Na治疗时,也会导致该细胞系生长显著延迟。此外,ONO-5046.Na治疗不仅在从第1天给药时,而且在肿瘤接种14天后、实体瘤开始生长时开始治疗,均可在8周时完全抑制肺内转移灶的出现。接受ONO-5046.Na治疗的小鼠在8周时的体重与对照小鼠相似,且在治疗期间看起来与对照小鼠一样健康。这些结果表明,NE抑制剂ONO-5046.Na可抑制NSCLC的原发和转移生长,且无明显副作用。